- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
While scaling up access to all treatment and prevention options that currently exist is essential, it is not sufficient. There remains a critical need for additional options. In addition to the introduction of oral-TDF based PrEP and the open-lable extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway. They're tackling virtually every intervention—from next-generation PrEP in the form of F/TAF, a drug that will soon be tested for efficacy as daily oral PrEP, to long-acting injectables, vaccines and antibody-mediated prevention.
This Report presents the latest findings from collation and analysis of viral hepatitis data obtained from the disease notification system, service statistics, seroprevalence studies and other research findings. Much hopeful that the local viral hepatitis picture can be painted accurately and fully, this is certainly limited by the nature and availability of data. The presence of biases in data per se and their interpretation need to be acknowledged in reading this Report.
Given the higher rates of acquisition seen across so-called key populations—members of highly burdened and underserved groups—it is critical to provide access to the research process such that they can participate and reap more immediate benefit of scientific progress. Greater efforts must be made to include key populations in this crucial process for the HIV prevention response to be truly impactful.
Excerpted from Px Wire.
Within the continuum of reproductive health care, antenatal care (ANC) provides a platform for important healthcare functions, including health promotion, screening and diagnosis, and disease prevention. It has been established that, by implementing timely and appropriate evidence-based practices, ANC can save lives.
Endorsed, by the UN Secretary-General, this is a comprehensive WHO guideline on routine ANC for pregnant women and adolescent girls. It aims to complement existing WHO guidelines on the management of specific pregnancy-related complications. The guidance aims to capture the complex nature of the issues surrounding ANC health care practices and delivery, and to prioritize person-centred health and well-being, not only the prevention of death and morbidity, in accordance with a human rights-based approach.
Keywords: ANC, women, pregnancy, children, adolescent
This paper reviews the latest global and local situation of hepatitis A and examines the prevention and control measures of hepatitis A in Hong Kong.
Hepatitis A is inflammation of the liver caused by the hepatitis A virus (HAV). It is one of the most frequent causes of foodborne infection. It occurs sporadically and in epidemics worldwide. Every year there are an estimated 1.4 million cases of hepatitis A worldwide. Regions with high HAV endemicity include parts of Africa and Asia.
The publication presents cascade of HIV testing, care and treatment services, 2014–2015 for Bangladesh, Bhutan, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor Leste.
Greatly expanded access to routine viral load testing will be a game-changer in the global response to AIDS. Routine viral load tests improve treatment quality and individual health outcomes for people living with HIV, contribute to prevention, and potentially reduce resource needs for costly second- and third-line HIV medicines.
In 2000, when the International AIDS Conference was last held in Durban, South Africa, a basic antiretroviral (ARV) regimen cost over US$10,000 per person per year (PPPY), multilateral programmes funding the fight against HIV, TB, and malaria did not exist, and many donors – such as the US government – had yet to provide a single dollar for antiretroviral treatment in resource-limited countries.
Whether it’s the rising price of the EpiPen, or new outbreaks of diseases, like Ebola, Zika and yellow fever, the rising costs of health technologies and the lack of new tools to tackle health problems, like antimicrobial resistance, is a problem in rich and poor countries alike.
Keywords: TRIPS, Antimicrobial resistance (AMR), health technology, access
Until recently, diagnosis and treatment of HCV was complex. Suitable tools for screening and diagnosis were lacking, and treatment was hampered by limited efficacy and severe side effects. New medicines for the treatment of HCV have revolutionized HCV treatment. Combinations of these new medicines, which are generally well-tolerated and effective, can cure HCV in 12 weeks. This offers a huge opportunity to address HCV, in particularly among HIV/HCV co-infected people, who are more vulnerable as they progress faster to serious disease than HCV mono-infected people.